Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

CORRECTION: Ossur Hf : Transactions in relation to share buyback program

Ossur Hf
Posted on: 20 Nov 17

This is a correction of the announcement from 17:00 20.11.2017 CET. Reason for the correction: "T" missing in the header, it should read "Transactions" instead of "ransactions"

Announcement from Össur  hf. No. 83/2017
Reykjavík, 20 November 2017

On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. 

The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 31 July 2018. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.1% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million.

The following transactions were made under the program in week 14, the period 13 November 2017 - 17 November 2017:

DateNo. of sharesAvg. purchase price DKKTransaction Value DKK
13 November 20178,24629.02239,278
14 November 20173,82728.96110,826
15 November 201760029.0017,400
16 November 201712,72529.06369,772
17 November 20176,59029.05191,456
Total    31,98829.03928,732

Össur has acquired 698,805 shares under the program at the average price of DKK 29.64. Following the above transactions Össur's holding of own shares is 8,815,410 corresponding to 2.02% of the Company's total share capital.

The share buyback program is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission delegated regulation No. 2016/1052.                                                                                                                                                                                                                   

Contact persons:

Jón Sigurðsson, President & CEO                                        Tel: +354 515 1300

Sveinn Sölvason, CFO                                                          Tel: +354 515 1300

Össur press releases by e-mail:  If you wish to receive Össur press releases by e-mail please register at the following web-site:  

About Össur   Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports and prosthetic limbs. A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the  market.  Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide.

Forward-Looking Statement  This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.


Share buy back transactions 13.11 - 17.11.2017

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ossur Hf via GlobeNewswire

Last updated on: 21/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.